Dianthus Total Current Liabilities from 2010 to 2024
| DNTH Stock | 23.83 0.03 0.13% |
Total Current Liabilities | First Reported 2017-12-31 | Previous Quarter 10 M | Current Value 15.7 M | Quarterly Volatility 2.9 M |
Check Dianthus Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Dianthus Therapeutics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 337.2 K, Interest Expense of 2.7 M or Selling General Administrative of 14.9 M, as well as many indicators such as Price To Sales Ratio of 18.02, Dividend Yield of 0.0 or PTB Ratio of 0.3. Dianthus financial statements analysis is a perfect complement when working with Dianthus Therapeutics Valuation or Volatility modules.
Dianthus | Total Current Liabilities |
Latest Dianthus Therapeutics' Total Current Liabilities Growth Pattern
Below is the plot of the Total Current Liabilities of Dianthus Therapeutics over the last few years. Total Current Liabilities is an item on Dianthus Therapeutics balance sheet that include short term debt, accounts payable, accrued salaries payable, payroll taxes payable, accrued liabilities and other debts. Total Current Liabilities of Dianthus Therapeutics are important to investors because some useful performance ratios such as Current Ratio and Quick Ratio require Total Current Liabilities to be accurate. It is the total amount of liabilities that a company is expected to pay within one year, including debts, accounts payable, and other short-term financial obligations. Dianthus Therapeutics' Total Current Liabilities historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Dianthus Therapeutics' overall financial position and show how it may be relating to other accounts over time.
| Total Current Liabilities | 10 Years Trend |
|
Total Current Liabilities |
| Timeline |
Dianthus Total Current Liabilities Regression Statistics
| Arithmetic Mean | 5,895,728 | |
| Geometric Mean | 4,611,392 | |
| Coefficient Of Variation | 70.47 | |
| Mean Deviation | 3,662,341 | |
| Median | 4,142,000 | |
| Standard Deviation | 4,154,786 | |
| Sample Variance | 17.3T | |
| Range | 11.8M | |
| R-Value | 0.74 | |
| Mean Square Error | 8.5T | |
| R-Squared | 0.54 | |
| Significance | 0 | |
| Slope | 685,755 | |
| Total Sum of Squares | 241.7T |
Dianthus Total Current Liabilities History
About Dianthus Therapeutics Financial Statements
Investors use fundamental indicators, such as Dianthus Therapeutics' Total Current Liabilities, to determine how well the company is positioned to perform in the future. Although Dianthus Therapeutics' investors may analyze each financial statement separately, they are all interrelated. Understanding these patterns can help investors make the right trading decisions.
| Last Reported | Projected for Next Year | ||
| Total Current Liabilities | 9.6 M | 9 M |
Currently Active Assets on Macroaxis
When determining whether Dianthus Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Dianthus Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Dianthus Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Dianthus Therapeutics Stock:Check out the analysis of Dianthus Therapeutics Correlation against competitors. For more detail on how to invest in Dianthus Stock please use our How to Invest in Dianthus Therapeutics guide.You can also try the Portfolio Backtesting module to avoid under-diversification and over-optimization by backtesting your portfolios.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Dianthus Therapeutics. If investors know Dianthus will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Dianthus Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share 7.22 | Revenue Per Share 0.19 | Quarterly Revenue Growth 1.351 | Return On Assets (0.19) | Return On Equity (0.26) |
The market value of Dianthus Therapeutics is measured differently than its book value, which is the value of Dianthus that is recorded on the company's balance sheet. Investors also form their own opinion of Dianthus Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Dianthus Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Dianthus Therapeutics' market value can be influenced by many factors that don't directly affect Dianthus Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Dianthus Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Dianthus Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Dianthus Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.